Table 3 Comparison of patient characteristics between those with and without drug resistance
Characteristic | Patients with TDR | Patients without TDR | OR (95% CI) | p-value |
|---|---|---|---|---|
Number (%) | Number (%) | |||
N=19 | N=136 | |||
Country of Birth | ||||
Canada | 12 (63.2%) | 79 (58.1%) | 1.44 (0.47, 4.62) | 0.48 |
Other | 7 (36.8%) | 57 (41.9%) | ||
Gender | ||||
Male | 18 (94.7%) | 97 (71.3%) | 7.18 (1.06, 309.13) | 0.03 |
Female | 1 (5.3%) | 39 (28.7%) | ||
Mean age (range) | 38 (23-49) | 37 (18-70) | 0.73 | |
Exposure Category | ||||
MSM | 13 (68.4%) | 48 (35.3%) | ||
IDU | 1 (5.3%) | 17 (12.5%) | ||
MSM/IDU | 1 (5.3%) | 1 (0.7%) | ||
HIV endemic | 2 (10.5%) | 32 (23.5%) | ||
Heterosexual | 0 | 35 (25.7%) | ||
Other | 0 | 1 (0.7%) | ||
Unknown | 2 (10.5%) | 2 (1.5%) | ||
MSM | 13 (68.4%) | 48 (35.3%) | 3.97 (1.30, 12.63) | 0.005 |
All other | 6 (31.6%) | 88 (64.7%) | ||
Clade | ||||
B | 18(94.7%) | 88 (64.7%) | 9.73 (1.45,417.43) | 0.009 |
Non-B | 1 (5.3%) | 48 (35.3%) | ||
CD4 Count | ||||
<200 | 6 (31.6%) | 41 (30.1%) | 0.97 | |
200-500 | 8 (42.1%) | 64 (47.1%) | ||
>500 | 5 (26.3%) | 29 (21.3%) | ||
Unknown | 0 | 2 (1.5%) | ||
Viral Load | ||||
<5,000 | 5 (21.1%) | 36 (27.2%) | 0.37 | |
5,000-10,000 | 3 (15.8%) | 13 (9.6%) | ||
10,000-100,000 | 8 (47.4%) | 57 (41.2%) | ||
>100,000 | 2 (10.5%) | 29 (21.3%) | ||
Unknown | 1 (5.3%) | 1 (0.7%) | ||
Time Between Diagnosis and Genotype | 0.07* | |||
<6 months | 17 (89.5%) | 88 (64.7%) | ||
6-12 months | 0 | 7 (5.1%) | ||
>12 months | 1 (5.3%) | 34 (25.5%) | ||
Unknown | 1 (5.3%) | 7 (5.1%) |